CALLEGARI, DONATELLA
 Distribuzione geografica
Continente #
NA - Nord America 586
EU - Europa 575
AS - Asia 201
AF - Africa 16
Totale 1.378
Nazione #
US - Stati Uniti d'America 585
IT - Italia 202
CN - Cina 126
IE - Irlanda 103
SE - Svezia 75
FR - Francia 69
FI - Finlandia 54
DE - Germania 32
TR - Turchia 30
SG - Singapore 27
CI - Costa d'Avorio 16
VN - Vietnam 14
BE - Belgio 13
CZ - Repubblica Ceca 7
GB - Regno Unito 7
HR - Croazia 3
RO - Romania 3
AT - Austria 2
NL - Olanda 2
TH - Thailandia 2
BG - Bulgaria 1
CA - Canada 1
IN - India 1
PL - Polonia 1
TW - Taiwan 1
UA - Ucraina 1
Totale 1.378
Città #
Chandler 132
Ann Arbor 122
Dublin 103
Parma 59
Dearborn 41
New York 36
Izmir 26
Ashburn 25
Shanghai 25
Beijing 22
Boardman 22
Singapore 21
Nanjing 19
Abidjan 16
Princeton 16
Dong Ket 14
Wilmington 14
Bremen 13
Shenyang 11
Brussels 10
Los Angeles 9
Modena 9
Jinan 7
Follonica 6
Helsinki 6
San Mateo 6
Soliera 6
Woodbridge 6
Brescia 5
Prata Di Pordenone 5
Brno 4
Dallas 4
Grafing 4
Hefei 4
Jiaxing 4
Kunming 4
Lubbock 4
Rome 4
Sant'ilario D'enza 4
Santa Clara 4
Ankara 3
Borås 3
Caorso 3
Düsseldorf 3
Fremont 3
Guangzhou 3
Hebei 3
Milan 3
Munich 3
Nanchang 3
Norwalk 3
Seattle 3
Trento 3
Trieste 3
Vigevano 3
Zagreb 3
Bangkok 2
Bergamo 2
Carpi 2
Changsha 2
Chicago 2
Fairfield 2
Hangzhou 2
Houston 2
Montegaldella 2
Palermo 2
Redmond 2
Rimini 2
Saviano 2
Vienna 2
Zhengzhou 2
Alessandria 1
Bari 1
Bologna 1
Chaoyang 1
Charlottesville 1
Chengdu 1
Chongqing 1
Des Moines 1
Edinburgh 1
Erlangen 1
Frankfurt am Main 1
Frontone 1
Fuzhou 1
Istanbul 1
Jacksonville 1
Kraków 1
La Villa 1
Leuven 1
Louvain 1
Magdeburg 1
Múggia 1
Ottawa 1
Parabita 1
Paris 1
Pavia 1
Philadelphia 1
Pune 1
Reggio Nell'emilia 1
Rho 1
Totale 959
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 206
Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties 127
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 119
Development of an orally bioavailable small molecule targeting Eph-ephrin system: in vitro and in vivo anticancer activity. 107
The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells 88
Discovery and development of small molecules targeting Eph-ephrin system in glioblastoma: an academic history 87
Eph-ephrin antagonism in tumor angiogenesis and growth: UniPR1331 preclinical evidence. 80
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 79
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 77
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 72
N-Acylethanolamine Acid Amidase (NAAA): Mechanism of Palmitoylethanolamide Hydrolysis Revealed by Mechanistic Simulations 72
L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib 68
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 66
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 64
Metadynamics Simulations Distinguish Short- and Long-Residence-Time Inhibitors of Cyclin-Dependent Kinase 8. 64
Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations 56
Totale 1.432
Categoria #
all - tutte 4.840
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.840


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020196 0 0 5 8 18 49 33 11 24 27 10 11
2020/2021195 10 6 20 30 14 11 15 9 39 9 6 26
2021/2022151 4 6 9 25 3 10 27 9 2 12 10 34
2022/2023410 35 51 26 44 38 43 3 26 119 4 19 2
2023/2024149 7 5 3 2 11 47 20 8 5 6 17 18
2024/202576 19 21 36 0 0 0 0 0 0 0 0 0
Totale 1.432